title: Treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
abstract: The use of imatinib, as part of front-line treatment and in combination with cytotoxic agents, has greatly improved the proportions of complete response and molecular remission, and overall outcome in adults with newly diagnosed Philadelphia chromosome acute lymphoblastic leukemia. New challenges have emerged with respect to induction of resistance to imatinib via ABL mutations. Several novel kinase inhibitors with significantly more potent anti-leukemic activity than imatinib are currently being developed.
authors.affiliation: Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL), Hematology Department, Edouard Herriot Hospital, Lyon, France. xavier.thomas@chu-lyon.fr
authors.forename: Xavier
authors.initials: X
authors.lastname: Thomas
authors.forename: Hervé
authors.initials: H
authors.lastname: Dombret
mesh_terms: D001549:Benzamides; D019008:Drug Resistance, Neoplasm; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000068877:Imatinib Mesylate; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000628:therapy; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl